Cargando…

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice

BACKGROUND: Limited information exists regarding tumor response to palbociclib plus an aromatase inhibitor (AI) versus AI alone in real-world practice. OBJECTIVE: To evaluate the real-world tumor response of palbociclib plus letrozole (PAL+LET) versus LET alone as first-line treatment for patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Brufsky, Adam, Liu, Xianchen, Li, Benjamin, McRoy, Lynn, Layman, Rachel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484164/
https://www.ncbi.nlm.nih.gov/pubmed/34338965
http://dx.doi.org/10.1007/s11523-021-00826-1
_version_ 1784577261236649984
author Brufsky, Adam
Liu, Xianchen
Li, Benjamin
McRoy, Lynn
Layman, Rachel M.
author_facet Brufsky, Adam
Liu, Xianchen
Li, Benjamin
McRoy, Lynn
Layman, Rachel M.
author_sort Brufsky, Adam
collection PubMed
description BACKGROUND: Limited information exists regarding tumor response to palbociclib plus an aromatase inhibitor (AI) versus AI alone in real-world practice. OBJECTIVE: To evaluate the real-world tumor response of palbociclib plus letrozole (PAL+LET) versus LET alone as first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer (HR+/HER2‒ MBC) in routine US clinical practice. PATIENTS AND METHODS: This retrospective analysis included HR+/HER2‒ MBC patients who initiated PAL+LET or LET as first-line treatment between February 2015 and September 2018 in the Flatiron Health Analytics database. Patients were followed until December 2018. Real-world best tumor response (rwBTR) was determined based on physicians’ assessment of radiologic evidence for change in burden of disease. RESULTS: Of the 1383 eligible patients who initiated PAL+LET or LET as first-line therapy in the Flatiron database, 968 patients had ≥ 1 tumor response assessment (662 received PAL+LET and 306 received LET). The rwBTR rate (complete response+partial response) in the first-line setting was 59.8% in the PAL+LET group and 39.2% in the LET group (odds ratio 2.31 (95% CI 1.75‒3.04), P < 0.0001). After 1:1 propensity-score matching, the rwBTR rate was 58.6% in the PAL+LET group versus 39.1% in the LET group (odds ratio 2.21 (95% CI 1.50‒3.25), P < 0.0001). CONCLUSIONS: This real-world analysis demonstrated that HR+/HER2‒ MBC patients were more likely to respond to PAL+LET compared to LET. These findings further showed the effectiveness of PAL+LET therapy in the real-world setting and support the combination as a standard of care for MBC. STUDY REGISTRATION: Pfizer; NCT04176354; registered November 25, 2019 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11523-021-00826-1.
format Online
Article
Text
id pubmed-8484164
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-84841642021-10-08 Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice Brufsky, Adam Liu, Xianchen Li, Benjamin McRoy, Lynn Layman, Rachel M. Target Oncol Original Research Article BACKGROUND: Limited information exists regarding tumor response to palbociclib plus an aromatase inhibitor (AI) versus AI alone in real-world practice. OBJECTIVE: To evaluate the real-world tumor response of palbociclib plus letrozole (PAL+LET) versus LET alone as first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer (HR+/HER2‒ MBC) in routine US clinical practice. PATIENTS AND METHODS: This retrospective analysis included HR+/HER2‒ MBC patients who initiated PAL+LET or LET as first-line treatment between February 2015 and September 2018 in the Flatiron Health Analytics database. Patients were followed until December 2018. Real-world best tumor response (rwBTR) was determined based on physicians’ assessment of radiologic evidence for change in burden of disease. RESULTS: Of the 1383 eligible patients who initiated PAL+LET or LET as first-line therapy in the Flatiron database, 968 patients had ≥ 1 tumor response assessment (662 received PAL+LET and 306 received LET). The rwBTR rate (complete response+partial response) in the first-line setting was 59.8% in the PAL+LET group and 39.2% in the LET group (odds ratio 2.31 (95% CI 1.75‒3.04), P < 0.0001). After 1:1 propensity-score matching, the rwBTR rate was 58.6% in the PAL+LET group versus 39.1% in the LET group (odds ratio 2.21 (95% CI 1.50‒3.25), P < 0.0001). CONCLUSIONS: This real-world analysis demonstrated that HR+/HER2‒ MBC patients were more likely to respond to PAL+LET compared to LET. These findings further showed the effectiveness of PAL+LET therapy in the real-world setting and support the combination as a standard of care for MBC. STUDY REGISTRATION: Pfizer; NCT04176354; registered November 25, 2019 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11523-021-00826-1. Springer International Publishing 2021-08-02 2021 /pmc/articles/PMC8484164/ /pubmed/34338965 http://dx.doi.org/10.1007/s11523-021-00826-1 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Brufsky, Adam
Liu, Xianchen
Li, Benjamin
McRoy, Lynn
Layman, Rachel M.
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
title Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
title_full Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
title_fullStr Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
title_full_unstemmed Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
title_short Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
title_sort real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in us clinical practice
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484164/
https://www.ncbi.nlm.nih.gov/pubmed/34338965
http://dx.doi.org/10.1007/s11523-021-00826-1
work_keys_str_mv AT brufskyadam realworldtumorresponseofpalbociclibplusletrozoleversusletrozoleformetastaticbreastcancerinusclinicalpractice
AT liuxianchen realworldtumorresponseofpalbociclibplusletrozoleversusletrozoleformetastaticbreastcancerinusclinicalpractice
AT libenjamin realworldtumorresponseofpalbociclibplusletrozoleversusletrozoleformetastaticbreastcancerinusclinicalpractice
AT mcroylynn realworldtumorresponseofpalbociclibplusletrozoleversusletrozoleformetastaticbreastcancerinusclinicalpractice
AT laymanrachelm realworldtumorresponseofpalbociclibplusletrozoleversusletrozoleformetastaticbreastcancerinusclinicalpractice